Today: 22 January 2026
Subscribe
Browse Category

Pharmaceuticals News 14 November 2025 - 18 November 2025

Kenvue (KVUE) Stock Plunges Amid Tylenol and Talc Fears – What’s Next?

KVUE Stock Today (Nov. 18, 2025): Shares Slip as Appeals Court Weighs Tylenol Cases; Dividend Cleared; Kimberly‑Clark Deal Spread Persists

At a glance — price & drivers (midday, Nov. 18, 2025) Market action and context KVUE softened today after Monday’s developments in federal litigation tied to claims that prenatal acetaminophen use raises autism risk. A three‑judge appeals panel questioned the lower court’s dismissal of those cases, opening the door to their potential return and keeping headline risk front‑and‑center for the…
18 November 2025
····
Arvinas (ARVN) Soars 14% as Investors Cheer Pipeline Reset and Jefferies Update

Arvinas (ARVN) Soars 14% as Investors Cheer Pipeline Reset and Jefferies Update

Arvinas (NASDAQ: ARVN) jumped in double digits on November 18, 2025 amid a focused pipeline reset, FDA momentum for vepdegestrant and attention at the Jefferies London Healthcare Conference. ARVN stock pops on November 18, 2025 Arvinas shares are in rally mode this Tuesday. By mid‑afternoon U.S. trading, ARVN is up more than 14% on the day, with intraday prices hovering…
18 November 2025
····
Novo Nordisk (NVO) Stock Tanks as Weight-Loss Empire Faces Boardroom Coup and Fierce Rivalry

Novo Nordisk Stock Today (Nov 18, 2025): $199 Wegovy/Ozempic Intro Offer Drives Focus; Controlling Shareholder Sells ConvaTec Stake; NVO Edges Lower

Published November 18, 2025 Summary: Novo Nordisk (NYSE: NVO) remains in the spotlight after rolling out a U.S. self‑pay price cut for Wegovy and Ozempic—plus a two‑month $199 introductory offer for new patients—while its controlling shareholder Novo Holdings exited its ConvaTec stake in London. U.S.-listed shares were modestly lower intraday as investors weighed near‑term pricing pressure against potential volume gains…
18 November 2025
···
Olema Pharmaceuticals (OLMA) Soars Over 200% After Roche Breast Cancer Trial Win — What It Means for Palazestrant and Investors on November 18, 2025

Olema Pharmaceuticals (OLMA) Soars Over 200% After Roche Breast Cancer Trial Win — What It Means for Palazestrant and Investors on November 18, 2025

Why OLMA Stock Is Exploding Today Olema Pharmaceuticals didn’t publish a press release or file anything with the SEC this morning. Yet, its stock rocketed nearly threefold in pre‑market trading on Tuesday, November 18, 2025. TipRanks The real catalyst comes from Roche. Roche’s giredestrant delivers a landmark Phase 3 win Roche’s Genentech unit announced that giredestrant, its investigational oral selective…
18 November 2025
····
Pfizer (PFE) Stock Today, November 17, 2025: Migraine Drug Launch in India, Metsera Deal Closes and New RSV Vaccine Data

Pfizer (PFE) Stock Today, November 17, 2025: Migraine Drug Launch in India, Metsera Deal Closes and New RSV Vaccine Data

Pfizer Inc. (NYSE: PFE) is back in the headlines today with a flurry of developments that span new product launches, obesity-drug M&A, fresh vaccine data and ongoing debate about whether its battered stock is finally a buy. As of this afternoon, Pfizer shares are trading around $25.28, little changed on the day, and still down roughly 55% from their late‑2022…
17 November 2025
··
Tonix Pharmaceuticals (TNXP) Jumps as TONMYA, First New Fibromyalgia Drug in 15 Years, Hits U.S. Pharmacies – November 17, 2025

Tonix Pharmaceuticals (TNXP) Jumps as TONMYA, First New Fibromyalgia Drug in 15 Years, Hits U.S. Pharmacies – November 17, 2025

Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) moved sharply higher today after the company confirmed that TONMYA™ (cyclobenzaprine HCl sublingual tablets), its newly approved fibromyalgia treatment, is now commercially available by prescription across the United States. GlobeNewswire TONMYA Officially Launches in the U.S. Tonix announced at 7:00 a.m. EST that TONMYA is available for pharmacy ordering nationwide and can now be…
17 November 2025
·
Galmed Pharmaceuticals (GLMD) Soars on New Cancer Drug Combo Data: What Today’s Breakthrough Means for Investors – November 17, 2025

Galmed Pharmaceuticals (GLMD) Soars on New Cancer Drug Combo Data: What Today’s Breakthrough Means for Investors – November 17, 2025

As of this afternoon, Galmed Pharmaceuticals shares were changing hands around $1.18, up roughly 13% on the day, with more than 41 million shares traded—massively above the stock’s usual daily volume. TipRanks What Galmed Announced Today From its headquarters in Ramat Gan, Israel, Galmed Pharmaceuticals Ltd. announced fresh results from its ongoing collaboration with Virginia Commonwealth University (VCU) on overcoming…
17 November 2025
····
Jazz Pharmaceuticals (JAZZ) Soars on Breakthrough Ziihera Phase 3 Results in Gastroesophageal Cancer – Key Updates for 17 November 2025

Jazz Pharmaceuticals (JAZZ) Soars on Breakthrough Ziihera Phase 3 Results in Gastroesophageal Cancer – Key Updates for 17 November 2025

Jazz Pharmaceuticals plc (NASDAQ: JAZZ) is in the spotlight today after announcing positive Phase 3 data for its cancer drug Ziihera® (zanidatamab‑hrii) in a large global trial for HER2‑positive gastroesophageal adenocarcinoma (GEA). The news has triggered sharp pre‑market moves in Jazz’s share price and its partners’ stocks, and could reshape the treatment landscape for a difficult‑to‑treat cancer. PR Newswire JAZZ…
17 November 2025
···
Johnson & Johnson’s $3.05 Billion Halda Therapeutics Deal Signals New Oncology Push After Stelara Patent Cliff

Johnson & Johnson’s $3.05 Billion Halda Therapeutics Deal Signals New Oncology Push After Stelara Patent Cliff

Johnson & Johnson has struck a $3.05 billion cash deal to acquire Halda Therapeutics, a privately held cancer-drug developer based in New Haven, Connecticut, in one of 2025’s biggest oncology takeovers so far. Reuters The move deepens J&J’s bet on cancer medicines just as sales of its long‑time blockbuster psoriasis drug Stelara are being hit hard by a wave of…
17 November 2025
··
Pfizer (PFE) Clinches $10B Metsera Deal, Beating Novo Nordisk — What the Winning Bid Means for the Obesity-Drug Race (Nov. 8, 2025)

Pfizer (PFE) Stock: 9 Things to Know Before the Market Opens on November 17, 2025

New York — As U.S. markets get ready to reopen on Monday, November 17, 2025, Pfizer (NYSE: PFE) heads into the week at a critical turning point: COVID cash flows are fading, an obesity-drug arms race is heating up, a major activist has just walked away, and management is betting billions on a new growth story. Here’s a concise but…
16 November 2025
····
Big Pharma’s Billion-Dollar Bet: Inside Eli Lilly’s $5B Virginia Factory and America’s New Drug Manufacturing Boom

Eli Lilly (LLY) Stock on November 15, 2025: Pricing Deal, Oral‑Obesity Pill Timeline, Q3 Beat Put Shares Near $1T — Outlook & Risks

Updated: November 15, 2025 Key takeaways Where LLY stands today (Nov. 15, 2025) As of 00:40 UTC on Nov. 15, LLY is ~$1,025 (day range $1,003–$1,033). The 52‑week range is roughly $624–$1,034, and third‑party dashboards peg market cap in the $920–$970B range, reflecting price swings and share count. On trailing metrics the stock trades near 50x earnings; on Lilly’s 2025…
15 November 2025
····
Pfizer Completes $10 Billion Metsera (MTSR) Buyout as Nasdaq Delists Stock Today

Pfizer Completes $10 Billion Metsera (MTSR) Buyout as Nasdaq Delists Stock Today

Metsera Inc. (NASDAQ: MTSR) stops trading today, November 14, 2025, as Pfizer closes its up to $10 billion obesity-drug acquisition. Here’s what Metsera shareholders and obesity-market investors need to know about the deal terms, CVR, delisting, and future milestones. Date: November 14, 2025Ticker: MTSR (Metsera, Inc.) – now being delisted On Friday, November 14, 2025, Metsera, Inc. officially disappears from…
14 November 2025
····
1 … 35 36 37 38 39 … 45

Stock Market Today

  • U.S. Stocks Rise as Trump Cancels Greenland Tariffs Threat
    January 22, 2026, 11:21 AM EST. U.S. stocks climbed on Thursday as President Donald Trump canceled proposed 10% tariffs on European countries over Greenland tensions, easing market fears. The S&P 500 gained 0.4%, the Dow rose 260 points (0.5%), and the Nasdaq increased 0.6%. This followed steep losses earlier in the week after Trump's initial tariff threat, reinforcing the pattern where markets react sharply and Trump reverses course. The Greenland deal framework with NATO leaders remains unsigned and vague. Treasury yields remained steady amid positive economic reports, including lower jobless claims and stronger growth than expected. Northern Trust surged 5.8% on robust earnings, while Procter & Gamble shares rose 2.1% despite slightly disappointing revenue.
Go toTop